Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Sinopharm Group Co's Shareholder Yield % was 13.34%.
Sinopharm Group Co (OTCPK:SHTDY) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Sinopharm Group Co Shareholder Yield % Related Terms
Sinopharm Group Co Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDY vs MCK, CAH, COR: Shareholder Yield % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Shareholder Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Sinopharm Group Co (SHTDY) has a Shareholder Yield % of 13.34% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #20 out of 113 companies in the Medical Distribution industry, placing it in the top 17.7%.
Is Sinopharm Group Co's Shareholder Yield % too high?
Sinopharm Group Co's current Shareholder Yield % is 13.34%. The Medical Distribution industry median Shareholder Yield % is 2.35. Sinopharm Group Co's value of 13.34% is 467.7% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #20 out of 113 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Shareholder Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #20 out of 113 companies for Shareholder Yield %. This places Sinopharm Group Co in the top 18% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 2.35. Sinopharm Group Co's value of 13.34% is 467.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Distribution company?
The median Shareholder Yield % among Medical Distribution companies is 2.35, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Shareholder Yield % of 13.34% is 467.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Shareholder Yield % is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Shareholder Yield % is 13.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.40, compared to a current price of $10.14 — trading 24.3% below its estimated fair value. The current Shareholder Yield % is 13.34% and 467.7% above the Medical Distribution industry median of 2.35. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Shareholder Yield % is 13.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.14 is trading 24.3% below its estimated GF Value™ of $13.40.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Shareholder Yield %: 13.34%
GF Value™: $13.40 vs. price of $10.14 (24.3% below fair value)
Industry Position: 467.7% above the Medical Distribution median (#20 of 113)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
